Targeted Genetics presents advances in synthetic gene delivery te...( E1A elicits a response in cells over-ex...)

E1A elicits a response in cells over-expressing HER-2/neu as well as in cells with normal levels of HER-2/neu, increasing the types of cancers for which the product may provide efficacy. In our Phase I trials of tgDCC-E1A as a single agent therapy, 11 of 16 evaluable patients with head and neck or breast cancer exhibited tumor shrinkage or stable disease. The animal data presented today demonstrate that tgDCC-E1A improves the efficacy of standard chemotherapeutic agents. These results validate a combination regimen and support the rationale for initiating clinical trials using tgDCC-E1A in combination with paclitaxel and cisplatin. Combination regimens may provide therapeutic benefit to a larger population of patients whose disease does not respond to stand ard treatments. Targeted Genetics intends to initiate a Phase I trial of tgDCC-E1A in combination with paclitaxel and cisplatin for ovarian cancer by the end of 1999."

E1A is a tumor inhibitor gene. Previous laboratory and animal studies have demonstrated E1A's ability to suppress metastases, induce apoptosis (programmed cell death) and reverse the over-expression of HER-2/neu, a cancer-causing gene. In patients with cancer, over-expression of the HER-2/neu oncogene is correlated with poor prognoses, increased tumor formation and metastasis and resistance to chemotherapeutic agents.

Advances in Systemic Gene Delivery Technology Dr. Anklesaria also presented data on Targeted Genetics' newest synthetic gene delivery system, designated Lipid Polycation DNA (LPD). The LPD delivery system was used to deliver E1A systemically to mice transplanted with human breast cancer tumors. The study, done in collaboration with Dr. Mien-Chie Hung at M.D. Anderson Cancer Center, compared LPD-E1A to E1A plasmid alone, a control gene delivered with LPD, paclitaxel alone and a combination of LPD-E1A and paclitaxel. The LPD-E1A formulation inhibited tumor growth while the
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
8-Dec-1999

Page: 1 2 3 4 5
Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents clinical data on E1A cancer gene therapy
8. Targeted Genetics presents advances in systemic gene delivery technology
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin